“TrialMaster®’s flexibility and OmniComm’s customer service were key factors in the selection process. We look forward to a long and continued relationship going forward.”

Annetine Gelijns, Co-Director of InChoir, Columbia University

“We have enjoyed a very successful relationship with OmniComm Systems for many years now. They bring to the table a first class EDC product, attention to detail and responsiveness to our needs. This is particularly important during the implementation process when timelines are tight. We have found them to be an ideal business partner.”

Tony Lamas, M.D., Director of Cardiovascular Research and Academic Affairs Mount Sinai Medical Center and Principal Investigator, TACT and PACT Studies, National Heart Lung & Blood Institute (NHLBI)

“Optimer has enjoyed a truly supportive relationship with OmniComm and has been very impressed with both their product and services.”

Michael N. Chang, Ph.D., President and CEO, Optimer

“Having worked with OmniComm and TrialMaster in the past, we knew they were the perfect match to satisfy our client's high level expectations. These trials are very sophisticated with complex design requirements that go far beyond your standard EDC implementation. OmniComm's trial build process and expertise allowed for a positive, iterative approach that produced the results our Sponsor was hoping for.”

Lloyd Baroody, CEO, Target Research Associates

“It is important for us to use a full service EDC provider whose capabilities include both a strong technology product and support services that would compliment our own efforts.”

Phillip Simmons, Director of Data Management and Biostatistics,
Kos Pharmaceuticals

“After looking at many EDC vendors we selected OmniComm's TrialMaster because of its flexibility, ease of use and rapid trial development time.”

Wim Makel, Managing Director, CRF-I

“APEX, a well-known, fast growing contract research organization based in Asia, selected OmniComm’s TrialMaster suite of EDC products after conducting an extensive evaluation of existing EDC products. “We concluded that TrialMaster offered the features, flexibility and price required by our company for deployment as our in-house standard.”

Albert Liou, CEO and Chairman, APEX International

“Asthmatx requires complete and accurate collection of clinical research data and the ability to analyze the data in the shortest time possible after a database “freeze” or lock. The capabilities of OmniComm’s’ EDC solution promises to save Asthmatx time and money. We selected the TrialMaster solution because of its ease of use and flexible structure. The integrated platform should enable Asthmatx to save valuable time and provide control over critical trial processes.”

Glendon E. French, President and CEO, Asthmatx

"We are pleased to be partnering with OmniComm, a company that has demonstrated its experience and ability in delivering comprehensive clinical data solutions on a global basis. Use of the TrialMaster system has allowed us to build a robust data management and safety review process and we are confident that TrialMaster will continue to enhance our efficiency in the drug discovery process."

Erik Henricson, MPH, CINRG Researcher and Coordinator of the Network

“Historically the use of EDC for Phase I studies has been relatively low primarily because of the very issues OmniComm’s TrialMaster Ph. I is now able to address which include rapid set-up time, easy to customize platform, smooth integration with laboratory and other external data and low cost. Since Catalyst is a rapidly growing full service CRO, we rely on technology driven products like TrialMaster Ph. I to enable us to perform more studies, faster with greater data quality compared to traditional methods all at a lower cost to our sponsors.”

Richard Anthony, Ph.D., Chairman and CEO, Catalyst

“OXiGENE has enjoyed a truly supportive relationship with OmniComm and has been very impressed with both their product and services.”

Scott Young, Chief Operating Officer, OXiGENE

“This relationship allows us to offer a broader range of clinical trial solutions and makes it easier for our customers to be able to implement electronic solutions on a global basis with a single contact and delivery focus. This collaboration is a key example of Concentrics’ strategy to provide our clients with cutting edge technology to lower costs, streamline clinical trial processes, facilitate decision making and better manager product portfolios.”

Julie Aker, President and CEO, Concentrics Research

Top